Citations

Showing 10 of 108094 citations.

Using Unsupervised Machine Learning Methods to Cluster Comorbidities in a Population‐Based Cohort of Patients With Rheumatoid Arthritis
Crowson, Cynthia S. , Gunderson, Tina M. , Davis, John M. , Myasoedova, Elena , Kronzer, Vanessa L. , Coffey, Caitrín M. , Atkinson, Elizabeth J. , Kronzer, Vanessa L , Myasoedova, Elena , Davis, John M

Mayo Clinic

Arthritis Care & Research | June 20, 2022 | Volume: 75 | Issue: 2 | Pages: 210-219

10.1002/acr.24973 | PMID 35724274 Get It

Objective To identify clusters of comorbidities in patients with rheumatoid arthritis (RA) using 4 methods and to compare to patients without RA. Methods In this retrospective, population‐based study, residents of 8 Minnesota counties with prevalent RA as of January 1, 2015 were identified. Age‐, sex‐, and county‐matched non‐RA comparators were selected from the same underlying population. Diagnostic codes were retrieved for 5 years before January 1, 2015. Using 2 codes ≥30 days apart, 44 previously defined morbidities and 11 nonoverlapping chronic disease categories based on Clinical Classifications Software were defined. Unsupervised machine learning methods of interest included hierarchical clustering, factor analysis, K‐means clustering, and network analysis. Results Two groups of 1,643 patients with and without RA (72% female; mean age 63.1 years in both groups) were studied. Clustering of comorbidities revealed strong associations among mental/behavioral comorbidities and among cardiovascular risk factors and diseases. The clusters were associated with age and sex. Differences between the 4 clustering methods were driven by comorbidities that are rare and those that were weakly associated with other comorbidities. Common comorbidities tended to group together consistently across approaches. The instability of clusters when using different random seeds or bootstrap sampling impugns the usefulness and reliability of these methods. Clusters of common comorbidities between RA and non‐RA cohorts were similar. Conclusion Despite the higher comorbidity burden in patients with RA compared to the general population, clustering comorbidities did not identify substantial differences in comorbidity patterns between the RA and non‐RA cohorts. The instability of clustering methods suggests caution when interpreting clustering using 1 method.
Distinct Reproductive Risk Profiles for Intrinsic-Like Breast Cancer Subtypes: Pooled Analysis of Population-Based Studies
Jung, Audrey , Ahearn, Thomas U. , Behrens, Sabine , Middha, Pooja , Bolla, Manjeet K. , Wang, Qin , Arndt, Volker , Aronson, Kristan J. , Brenner, Hermann , Eriksson, Mikael , Evans, D. Gareth , Hadjisavvas, Andreas , Haiman, Christopher A. , Håkansson, Niclas , Hamann, Ute , Hoppe, Reiner , Howell, Anthony , Hunter, David J. , Kosma, Veli‐Matti , Lissowska, Jolanta , Loizidou, Maria A. , Mannermaa, Arto , Maurer, Tabea, Olsson, Håkan , Patel, Alpa V , Perou, Charles M. , Shibli, Rana , Stone, Jennifer , Vachon, Celine M. , Wang, Sophia , Wu, Anna H. , Yang, Xiaohong R. , Zheng, Wei , Easton, Douglas F. , Chatterjee, Nilanjan , García‐Closas, Montserrat , Chang‐Claude, Jenny , Olsson, Håkan , Jung, Audrey Y , Becher, Heiko , Brenner, Hermann , Canzian, Federico , Czene, Kamila , Eliassen, A Heather , Figueroa, Jonine D , Fritschi, Lin , Gabrielson, Marike , Giles, Graham G , Guénel, Pascal , Hadjisavvas, Andreas , Håkansson, Niclas , Hall, Per N , Hüsing, Anika , Koutros, Stella , Kraft, Peter , Marchand, Loïc Le , Lissowska, Jolanta , Loizidou, Maria A , Mannermaa, Arto , Murphy, Rachel A , Olsson, Håkan , Patel, Alpa V , Perou, Charles M , Shu, Xiao-Ou , Southey, Melissa C , Stone, Jennifer , Tamimi, Rulla M , Vachon, Celine M. , Wolk, Alicja , Dunning, Alison M , Pharoah, Paul D P , Easton, Doug , Milne, Roger L , Schmidt, Marjanka K , García-Closas, Montserrat , Chang-Claude, Jenny , Behrens, Sabine , Evans, D Gareth , Arndt, Volker , Kapoor, Pooja Middha , Zheng, Wei , Eriksson, Mikael , Wang, Sophia S , Wang, Qin , Augustinsson, Annelie , Freeman, Laura E. Beane , Becher, Heiko , Canzian, Federico , Carey, Lisa A. , Czene, Kamila , Eliassen, A. Heather , Figueroa, Jonine D. , Fritschi, Lin , Gabrielson, Marike , Giles, Graham G. , Guénel, Pascal , Hopper, John L. , Hüsing, Anika , Kaaks, Rudolf , Koutros, Stella , Kraft, Peter , Lacey, James V. , Marchand, Loı̈c Le , Murphy, Rachel A. , Olshan, Andrew F. , Rennert, Gad , Shu, Xiao‐Ou , Southey, Melissa C. , Tamimi, Rulla M. , Teras, Lauren R. , Troester, Melissa A. , Truong, Thérèse , Wolk, Alicja , Dunning, Alison M. , Pharoah, Paul D.P. , Milne, Roger L. , Schmidt, Marjanka K.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | June 20, 2022 | Volume: 114 | Issue: 12 | Pages: 1706-1719

10.1093/jnci/djac117 | PMID 35723569 Get It

AbstractBackgroundReproductive factors have been shown to be differentially associated with risk of estrogen receptor (ER)-positive and ER-negative breast cancer. However, their associations with intrinsic-like subtypes are less clear.MethodsAnalyses included up to 23 353 cases and 71 072 controls pooled from 31 population-based case-control or cohort studies in the Breast Cancer Association Consortium across 16 countries on 4 continents. Polytomous logistic regression was used to estimate the association between reproductive factors and risk of breast cancer by intrinsic-like subtypes (luminal A-like, luminal B-like, luminal B-HER2–like, HER2-enriched–like, and triple-negative breast cancer) and by invasiveness. All statistical tests were 2-sided.ResultsCompared with nulliparous women, parous women had a lower risk of luminal A-like, luminal B-like, luminal B-HER2–like, and HER2-enriched–like disease. This association was apparent only after approximately 10 years since last birth and became stronger with increasing time (odds ratio [OR] = 0.59, 95% confidence interval [CI] = 0.49 to 0.71; and OR = 0.36, 95% CI = 0.28 to 0.46 for multiparous women with luminal A-like tumors 20 to less than 25 years after last birth and 45 to less than 50 years after last birth, respectively). In contrast, parous women had a higher risk of triple-negative breast cancer right after their last birth (for multiparous women: OR = 3.12, 95% CI = 2.02 to 4.83) that was attenuated with time but persisted for decades (OR = 1.03, 95% CI = 0.79 to 1.34, for multiparous women 25 to less than 30 years after last birth). Older age at first birth (Pheterogeneity < .001 for triple-negative compared with luminal A-like breast cancer) and breastfeeding (Pheterogeneity < .001 for triple-negative compared with luminal A-like breast cancer) were associated with lower risk of triple-negative breast cancer but not with other disease subtypes. Younger age at menarche was associated with higher risk of all subtypes; older age at menopause was associated with higher risk of luminal A-like but not triple-negative breast cancer. Associations for in situ tumors were similar to luminal A-like.ConclusionsThis large and comprehensive study demonstrates a distinct reproductive risk factor profile for triple-negative breast cancer compared with other subtypes, with implications for the understanding of disease etiology and risk prediction.
Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma
Ung, Choong Yong , Levee, Taylor M., Zhu, Shizhen , Ung, Choong Y, Yeo, Kok Siong , Zhang, Cheng , Correia, Cristina , Li, Hu

Mayo Clinic

Computational and Structural Biotechnology Journal | June 20, 2022 | Volume: 20 | Issue: No issue available | Pages: 3291-3303

10.1016/j.csbj.2022.06.024 | PMID 35832612 Get It

2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty
Goodman, Susan M. , Springer, Bryan D. , Davis, Marshall, Fernández, David , Figgie, Mark P. , Finlayson, Heather, George, Michael , Giles, Jon T. , Gililland, Jeremy M. , Klatt, Brian A., MacKenzie, Ronald, Russell, Linda , Sah, Alexander P. , Johnson, Beverly , Mandl, Lisa A. , Turgunbaev, Marat, Turner, Amy S. , Yates, Adolph J. , George, Michael , Giles, Jon T , Miller, Andy , Mandl, Lisa A , Turner, Amy S , Goodman, Susan M , Chen, Antonia F. , Fernández, David , Michaud, Kaleb D. , Abdel, Matthew P. , Sculco, Peter K. , Singh, Jasvinder A.

Mayo Clinic

Arthritis & Rheumatology | June 20, 2022 | Volume: 74 | Issue: 9 | Pages: 1464-1473

10.1002/art.42140 | PMID 35722708 Get It

Objective To develop updated guidelines for the perioperative management of disease‐modifying medications for patients with rheumatic diseases, specifically those with inflammatory arthritis (IA) and those with systemic lupus erythematosus (SLE), undergoing elective total hip arthroplasty (THA) or elective total knee arthroplasty (TKA). Methods We convened a panel of rheumatologists, orthopedic surgeons, and infectious disease specialists, updated the systematic literature review, and included currently available medications for the clinically relevant population, intervention, comparator, and outcomes (PICO) questions. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to rate the quality of evidence and the strength of recommendations using a group consensus process. Results This guideline updates the 2017 recommendations for perioperative use of disease‐modifying antirheumatic therapy, including traditional disease‐modifying antirheumatic drugs, biologic agents, targeted synthetic small‐molecule drugs, and glucocorticoids used for adults with rheumatic diseases, specifically for the treatment of patients with IA, including rheumatoid arthritis and spondyloarthritis, those with juvenile idiopathic arthritis, or those with SLE who are undergoing elective THA or TKA. It updates recommendations regarding when to continue, when to withhold, and when to restart these medications and the optimal perioperative dosing of glucocorticoids. Conclusion This updated guideline includes recently introduced immunosuppressive medications to help decision‐making by clinicians and patients regarding perioperative disease‐modifying medication management for patients with IA and SLE at the time of elective THA or TKA.
Enterochromaffin Cells–Gut Microbiota Crosstalk: Underpinning the Symptoms, Pathogenesis, and Pharmacotherapy in Disorders of Gut-Brain Interaction
Wei, Lai , Singh, Rajan , Ghoshal, Uday C. , Ghoshal, Uday C , Singh, Rajan

Mayo Clinic

Journal of Neurogastroenterology and Motility | June 20, 2022 | Volume: 28 | Issue: 3 | Pages: 357-375

10.5056/jnm22008 | PMID 35719046 Get It

P36 Knowledge, attitudes, and awareness of contraceptive choices in women with inflammatory bowel disease
Liu, Eleanor , Erande, Aditi, Farraye, Jennifer , Cannon, Rachel , Limdi, Jimmy K. , Woodhams, Elisabeth J. , Farraye, Francis A.

Mayo Clinic

Poster presentations | June 20, 2022 | Volume: No volume available | Issue: No issue available | Pages: A55.1-A55

10.1136/gutjnl-2022-bsg.96 Get It

P28 Effect of endoscopic disease criteria on endoscopic outcomes in the SEAVUE study
Allez, Matthieu , Lewis, James D. , Gasink, Chrispher, Hoops, Tim, Izanec, James , Scherl, Ellen , Pannacione, Remo, Sandborn, William J. , Lewis, James D , Hanauer, Stephen B. , Danese, Silvio , Irving, Peter Miles , Gasink, Christopher , Hoops, Timothy, Ma, Tony, Loftus, Edward V. , Sands, Bruce E

Mayo Clinic

Poster presentations | June 20, 2022 | Volume: No volume available | Issue: No issue available | Pages: A50-A52

10.1136/gutjnl-2022-bsg.90 Get It

O34 Barriers to faecal occult blood testing as a screening tool in a Middle Eastern country
Abdulelah, Zaid A. , Alqaisieh, Mohammad , Abdulelah, Ahmed , Khanfar, Asim , Hammad, Nouran , Masoud, Eyad Al, Odeh, Qusai, Alshrouf, Mohammad Ali , Abd-Alrahman, Haitham, Khatib, Maissa, Khatib, M Amer

Mayo Clinic

Oral presentations | June 20, 2022 | Volume: No volume available | Issue: No issue available | Pages: A21.1-A21

10.1136/gutjnl-2022-bsg.34 Get It

O30 Closure of perianal fistula in patients receiving ustekinumab in the SEAVUE and STARDUST trials
Laurent, Peyrin-Biroulet, Gasink, Christopher , Hoops, Timothy, Izanec, James , Nazar, Maciej, Bravatà, Ivana, Lahaye, Marjolein, Panaccione, Remo , Ma, Tony Xuyen , Irving, Peter Miles , Loftus, Edward V. , Danese, Silvio , Sands, Bruce E

Mayo Clinic

Oral presentations | June 20, 2022 | Volume: No volume available | Issue: No issue available | Pages: A17-A17

10.1136/gutjnl-2022-bsg.30 Get It

2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty
Goodman, Susan M. , Springer, Bryan D. , Davis, Marshall, Fernández, David , Figgie, Mark P. , Finlayson, Heather, George, Michael , Giles, Jon T. , Gilliland, Jeremy, Klatt, Brian A., MacKenzie, Ronald, Russell, Linda , Sah, Alexander P. , Johnson, Beverly , Mandl, Lisa A. , Turgunbaev, Marat, Turner, Amy S. , Yates, Adolph J. , Gililland, Jeremy M. , George, Michael , Giles, Jon T , Miller, Andy , Mandl, Lisa A , Turner, Amy S , Goodman, Susan M , Chen, Antonia F. , Fernández, David , Michaud, Kaleb D. , Abdel, Matthew P. , Sculco, Peter K. , Singh, Jasvinder A.

Mayo Clinic

Arthritis Care & Research | June 20, 2022 | Volume: 74 | Issue: 9 | Pages: 1399-1408

10.1002/acr.24893 | PMID 35718887 Get It

ObjectiveTo develop updated guidelines for the perioperative management of disease‐modifying medications for patients with rheumatic diseases, specifically those with inflammatory arthritis (IA) and those with systemic lupus erythematosus (SLE), undergoing elective total hip arthroplasty (THA) or elective total knee arthroplasty (TKA).MethodsWe convened a panel of rheumatologists, orthopedic surgeons, and infectious disease specialists, updated the systematic literature review, and included currently available medications for the clinically relevant population, intervention, comparator, and outcomes (PICO) questions. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to rate the quality of evidence and the strength of recommendations using a group consensus process.ResultsThis guideline updates the 2017 recommendations for perioperative use of disease‐modifying antirheumatic therapy, including traditional disease‐modifying antirheumatic drugs, biologic agents, targeted synthetic small‐molecule drugs, and glucocorticoids used for adults with rheumatic diseases, specifically for the treatment of patients with IA, including rheumatoid arthritis and spondyloarthritis, those with juvenile idiopathic arthritis, or those with SLE who are undergoing elective THA or TKA. It updates recommendations regarding when to continue, when to withhold, and when to restart these medications and the optimal perioperative dosing of glucocorticoids.ConclusionThis updated guideline includes recently introduced immunosuppressive medications to help decision‐making by clinicians and patients regarding perioperative disease‐modifying medication management for patients with IA and SLE at the time of elective THA or TKA.